WALTHAM, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of seven abstracts at the 2015 American Society of Clinical Oncology (ASCO) annual meeting, May 29 to June 2, 2015, in Chicago. In addition, TESARO will host an investor and analyst briefing in Chicago on Saturday, May 30 at 6:30 PM local time in conjunction with the ASCO annual meeting.
Presentation Details:
| Rolapitant |
| Saturday, May 30, 2015, 1:15 PM to 4:45 PM |
| Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). |
| Abstract: 9615, Poster Board: 274, Location: S Hall A |
| Saturday, May 30, 2015, 1:15 PM to 4:45 PM |
| Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy. |
| Abstract: 9618, Poster Board: 277, Location: S Hall A |
| Saturday, May 30, 2015, 1:15 PM to 4:45 PM |
| Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC). |
| Abstract: 9622, Poster Board: 281, Location: S Hall A |
| Niraparib |
| Saturday, May 30, 2015, 1:15 PM to 4:45 PM |
| Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors. |
| Abstract: 5532, Poster Board: 90, Location: S Hall A |
| Saturday, May 30, 2015, 1:15 PM to 4:45 PM |
| A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens. |
| Abstract #TPS5609, Poster Board #165a, Location: S Hall A |
| Saturday, May 30, 2015, 1:15 PM to 4:45 PM |
| ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. |
| Abstract #TPS5607, Poster Board #164a, Location: S Hall A |
| TSR-011 |
| Monday, June 1, 2015, 8:00 AM to 11:30 AM |
| Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. |
| Abstract #8063, Poster Board #386, Location: S Hall A |
Rolapitant, niraparib and TSR-011 are investigational product candidates that have not been approved by any regulatory agencies.
Investor Briefing and Webcast
TESARO will host an investor and analyst briefing in Chicago on Saturday, May 30 at 6:30 PM local time in conjunction with the ASCO annual meeting. At this briefing, TESARO management will provide a business overview and pipeline update, and will answer questions from investors and analysts. This event will be webcast live and archived for 30 days, and may be accessed from the TESARO Investor Events and Presentations webpage at www.tesarobio.com.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.